Diabetic Macular Edema News and Research

RSS

Fluid can leak into the center of the macula, the part of the eye where sharp, straight-ahead vision occurs. The fluid makes the macula swell, blurring vision. This condition is called macular edema. It can occur at any stage of diabetic retinopathy, although it is more likely to occur as the disease progresses. About half of the people with proliferative retinopathy also have macular edema.

New treatment targeting aging cells could offer lasting relief for diabetic macular edema

Targeting senescent cells in the retina with a BCL-xL inhibitor shows promise as a durable treatment for diabetic macular edema, potentially offering long-term visual function improvements.

8 Feb 2024

Falk Trust awards $1.35 million to Case Western Reserve researchers for cancer and diabetic retinopathy treatments

A combined $1.35 million from the Dr. Ralph and Marian Falk Medical Research Trust was awarded to two researchers from the Case Western Reserve University School of Medicine to advance their work on finding more effective treatments-;and better options-;for two debilitating diseases.

17 Nov 2023

The role of caffeine in preventing diabetic retinopathy

Moderate and high caffeine intake offered protection against the development of diabetic retinopathy.

5 Mar 2023

Early treatment of diabetes-related eye disease does not improve visual acuity

While early treatment of diabetes-related eye disease slowed progression to severe disease, it did not improve visual acuity compared with treating more severe disease once it developed, according to a clinical study from the DRCR Retina Network.

7 Feb 2023

A stepped regimen of anti-VEFG drugs leads to good vision outcomes in diabetic macular edema

Clinical trial results from the DRCR Retina Network suggest that a specific step strategy, in which patients with diabetic macular edema start with a less expensive medicine and switch to a more expensive medicine if vision does not improve sufficiently, gives results similar to starting off with the higher-priced drug.

14 Jul 2022

AI could predict treatment demand for chronic eye diseases

Age-related macular degeneration (AMD) is the most common cause of vision loss in people over 50. Up to 12 percent of those over 80 have the chronic disease.

8 Jun 2021

Early treatment with anti-VEGF injections slows diabetic retinopathy

Early treatment with anti-VEGF injections slowed diabetic retinopathy in a clinical study from the DRCR Retina Network (DRCR.net). However, two years into the four-year study its effect on vision was similar to standard treatment, which usually begins at the onset of late disease.

31 Mar 2021

New mobile app can help people diagnosed with glaucoma

Researchers from City, University London, supported by Allergan Pharmaceuticals and Glaucoma UK, have today released the latest edition of an app to help people newly diagnosed with glaucoma.

8 Mar 2021

Common medication used to treat diabetic macular edema is less effective in Black patients

A medication frequently used to treat diabetic macular edema, which is the most common cause of blindness in people with diabetes, is less effective when used to treat the condition in Black patients, new study results show.

22 Oct 2020

Phase 2 clinical trial to examine the effects of razuprotafib on COVID-19 patients

Researchers at the University of Cincinnati and UC Health will host a Phase 2 clinical trial (NCT04511650) to examine the effects of a drug that targets blood vessel inflammation and injury in patients with COVID-19.

22 Sep 2020

New eye drops could prevent vision loss after retinal vein occlusion

Researchers at Columbia University Irving Medical Center have developed eye drops that could prevent vision loss after retinal vein occlusion, a major cause of blindness for millions of adults worldwide.

29 Jun 2020

Preclinical data of Ocugen's OCU400 genetic modifier published in Nature Gene Therapy

Ocugen, Inc., a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved ophthalmic diseases, announced today the publication in Nature Gene Therapy of preclinical data of nuclear hormone receptor gene NR2E3 as a genetic modifier and therapeutic agent to treat multiple retinal degenerative diseases.

3 Mar 2020

Helper protein exacerbates diabetic macular edema

In a recent study using mice, lab-grown human retinal cells and patient samples, Johns Hopkins Medicine scientists say they found evidence of a new pathway that may contribute to degeneration of the light sensitive tissue at the back of the eye.

27 Nov 2019

Retinal macular damage linked to sleep apnea in diabetes

A new Taiwanese study presented on October 14, 2019, at the Annual Meeting of the American Academy of Ophthalmology, reports that macular edema in diabetes occurs more often in those who have severe sleep apnea.

15 Oct 2019

Sleep apnea is a risk factor for developing diabetic macular edema, study shows

New research from Taiwan shows that severe sleep apnea is a risk factor for developing diabetic macular edema, a complication of diabetes that can cause vision loss or blindness. Diabetic macular edema was also more difficult to treat in patients with severe sleep apnea.

14 Oct 2019

Inflammasome, Boehringer Ingelheim team up to develop new therapies for retinal diseases

Boehringer Ingelheim and Inflammasome Therapeutics Inc. (Inflammasome) today announced they have entered into a co-development and license agreement to develop up to three therapies for patients with retinal diseases.

From Boehringer Ingelheim International GmbH 25 Sep 2019

HbA1c analyzer identifies diabetics with poor glycemic control and high risk of sight loss

This HbA1c analyzer is successfully supporting improved medical management of patients with sight-threatening diabetic retinopathy (STDR).

From EKF Diagnostics 16 Jul 2019

A new strategy for managing diabetic macular edema in people with good vision

A change to the approach for treating diabetic macular edema may be on the way, thanks to a study published today in the Journal of the American Medical Association.

2 May 2019

Experimental drug may be twice as good at fighting vision loss as previously thought

In studies with lab-grown human cells and in mice, Johns Hopkins Medicine researchers have found that an experimental drug may be twice as good at fighting vision loss as previously thought.

11 Apr 2019

New cellular atlas could provide a deeper insight into blinding diseases

When it comes to understanding how neurons connect to form circuits in the brain, scientists for decades have turned to the retina of the humble laboratory mouse as an ideal model organism. But as a model for vision and vision-related diseases, mice simply aren't equipped.

22 Feb 2019